NNP
EBS icon

Nachman Norwood & Parrott’s Emergent Biosolutions EBS Stock Holding History

Nachman Norwood & Parrott’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-81
Closed -$8K – 474
2020
Q3 		$8K Buy
+81
New +$8.73K ﹤0.01% 812

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Nachman Norwood & Parrott's EBS Position: Q4 2020 in Review

Nachman Norwood & Parrott sold out of Emergent Biosolutions (EBS) in Q4 2020, closing a stake of 81 shares — an estimated $8K sold.

Nachman Norwood & Parrott first reported a position in EBS in Q3 2020 and held it in 1 quarter. The position peaked at $8K in Q3 2020. 353 funds tracked by Wall St. Rank hold EBS as of Q4 2020.

  • Nachman Norwood & Parrott reported no remaining Emergent Biosolutions position as of Q4 2020 after selling out during the quarter.
  • Nachman Norwood & Parrott sold 81 Emergent Biosolutions shares in Q4 2020, an estimated $8K.
  • Nachman Norwood & Parrott first reported a position in Emergent Biosolutions in Q3 2020 and held it in 1 quarter.
  • Nachman Norwood & Parrott's Emergent Biosolutions position peaked at $8K in Q3 2020.
  • 353 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2020.

Based on Nachman Norwood & Parrott's 13F filing for Q4 2020, filed 19 Jan 2021.